Different tendencies of changes in hydrolytic enzyme activities in sera from prostatic cancer patients with or without bone metastasis.

Teiichiro Aoyagi, Hironobu Umezawa, T Niijima, Takahito Hara(Takeda (Japan)), T Umeda, Takeshi Wada, Tetsuji Tanaka(Wakayama Medical University)

PubMed

April 1, 1984

Cited by 1

Related Papers

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

|PubMed|2003|427

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

|Proceedings of the National Academy of Sciences|2018|172

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

|Bioorganic & Medicinal Chemistry|2011|126

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

|The Journal of Steroid Biochemistry and Molecular Biology|2012|116

Androgen Receptor and Invasion in Prostate Cancer

|Cancer Research|2008|115